The Future of Central Nervous System Diseases Therapeutics

The Future of Central Nervous System Diseasesthe price differentials that are observed in US at
Therapeutics - Market Forecasts to 2015,a higher rate compared to other regions as well
Competitive Benchmarking, Product Pipeline andas the higher volume of diseased and
Deals Analysispharmacotherapy treated population.
This report provides key data, information andGlobal CNS Therapeutics Market: The Entry of
analysis on the global CNS therapeutics market.Generic Substitutes at Substantially Lower Prices
The report provides market landscape,is Forecast to Be a Major Threat for Primary
competitive landscape and market trendsDrug Manufacturers
information on seven disease categories whichGlobally, the US remains the largest sector in
include; Alzheimer’s disease, Parkinson’sterms of revenues. The US CNS therapeutics
disease, Schizophrenia and Bi-polar disorder, Majormarket in 2008 represented 52 % share over the
Depressive Disorder, Anxiety and Panic disorder,total CNS therapeutics market. Countries like
Attention Deficit Hyperactivity Disorder andChina and India have been identified as potential
Insomnia. The report also provides annualizedemerging markets for major pharmaceutical
market revenues data from 2000 to 2008,companies to invest in. A major factor posing a
forecast until 2015 for all the mentioned diseasethreat to this market is the expiration of patents
sectors. The report covers seven geographiesfor many block buster drugs in the next three
which include; the US, the UK, Germany, France,years. The entry of generic substitutes at
Spain and Italy and Japan. This report providessubstantially lower prices could be very debilitating
comprehensive information on the key trendsfor major manufacturers. Markets like Japan and
effecting these categories, and key analyticalother south Asian countries have shown increasing
content on the market dynamics. The report alsoacceptance of generics under their reimbursement
reviews the competitive landscape in terms ofprotocols. European countries face high risk from
mergers and acquisitions, pipeline products andparallel importing coupled with effective bans on
technology offerings. In-depth analysis of thethe reimbursements for certain CNS diseases.
report is based on propriety databases, primaryGlobal CNS Therapeutics Market: Key Trends
and secondary research and in house analysis byThe report analyzed environmental and industry
experts. ( )trends to assess the market evolution. Most
CNS Therapeutics Market is Forecast To Showtrends observed in the pharmaceutical industry
Slow Growth Till 2015support the forecasting models, drivers and
The global CNS therapeutics market was valuedbarriers outlined above. The top pharmaceuticals
at $99 billion in 2008 and will be driven by thecompanies are seeing rapid increases in research
increasing ageing population and the steadyand development costs accompanied by declining
increase in incidence rates of CNS complications.drug sales. DTC campaigns as promotional tactics
This market is expected to grow to $121 billionare being used increasingly across the
with a CAGR of 2.8% by year 2015. The CNSpharmaceutical industry. Reimbursements for
markets in US, EU5 (includes UK, France,almost all therapeutic areas, including CNS, are
Germany, Italy and Spain) and Japan. Of all theunder severe pressure. Taken together the
covered countries, the market size in US was theindustry and environmental trends suggest that
largest as compared to other regions. The marketCNS therapeutic area is likely to see increasing
is also growing the fastest in US as compared tomarket value in the next few years.
other regions. This is explained primarily by both